TIF News (IT)

”Blood Transfusion in Thalassaemia”: Save the Date for the Next TIF Webinar for Medical Specialists

”Blood Transfusion in Thalassaemia”: Save the Date for the Next TIF Webinar for Medical Specialists

TIF´s brand new Webinar, entitled ”Blood Transfusion in Thalassaemia” and organised as part of the eThalED Course, will be held on Monday, 31 August 2020, 15:00-16:00 EEST / 13:00-14:00 BST.…
TIF Publishes its Annual Report for 2019

TIF Publishes its Annual Report for 2019

This Annual Report showcases the Federation’s intensive efforts that took place in 2019 with the aim to ensure equal access to quality healthcare for every patient with thalassaemia and haemoglobin…
Viral Hepatitis & Thalassaemia: Q&A with Prof. John Koskinas

Viral Hepatitis & Thalassaemia: Q&A with Prof. John Koskinas

On the occasion of today´s World Hepatitis Day and with the aim of informing and raising awareness among patients with thalassaemia – and not only – about viral hepatitis that…
”Liver Disease & Thalassaemia”: En route to the 3rd TIF Webinar for Medical Specialists

”Liver Disease & Thalassaemia”: En route to the 3rd TIF Webinar for Medical Specialists

Tune in for TIF’s upcoming webinar on ”Liver Disease & Thalassaemia” for Medical Specialists, organised in the context of our eThalED Course on Friday, 31 July, EEST 15:00-16:00. Prof. Geoffrey Dusheiko, Emeritus…
TIF.ACCESS: A Global TIF Initiative for the Promotion of the Availability & Accessibility of Innovative Therapies

TIF.ACCESS: A Global TIF Initiative for the Promotion of the Availability & Accessibility of Innovative Therapies

The swift scientific progress made in the field of thalassaemia research has gained momentum with the market authorisations of both the Zynteglo Gene Therapy by the European Medicines Agency (EMA)…
COVID-19 and Thalassaemia: A Position Statement of the Thalassaemia International Federation

COVID-19 and Thalassaemia: A Position Statement of the Thalassaemia International Federation

Many patients with haemoglobinopathies, including thalassaemia and sickle cell disease, are at increased risk of developing severe complications from the coronavirus disease 2019 (COVID‐19). Although epidemiologic evidence concerning the novel…
TIF Postpones its International Conference on Thalassaemia to 2021

TIF Postpones its International Conference on Thalassaemia to 2021

Being mindful of the COVID-19 situation and wanting to ensure participants’ safety, TIF has taken the decision to postpone its long-awaited ’15th International Conference on Thalassaemia & other Haemoglobinopathies‘ & the ’17th TIF…
TIF Position Statement on the Use of DEHP Plasticisers in Medical Devices

TIF Position Statement on the Use of DEHP Plasticisers in Medical Devices

The safety concerns linked to the use of DEHP plasticizers, a manufactured chemical common in blood bags and PVC intravenous fluid sets, has been explored – and even questioned –…
Thalassaemia Prior and Consequent to COVID-19 Pandemic: The Perspective of Thalassaemia International Federation (TIF)

Thalassaemia Prior and Consequent to COVID-19 Pandemic: The Perspective of Thalassaemia International Federation (TIF)

Patients with haemoglobin disorders, particularly β-thalassaemia or sickle cell disease (SCD) or combined forms, on account of their underlying disease pathology and associated (iron load mainly in the case of…
Gene Therapy & Thalassaemia: A TIF Survey

Gene Therapy & Thalassaemia: A TIF Survey

Millions of people worldwide suffer from inherited non-malignant blood disorders like thalassaemia and sickle cell disease. The culprit: genetic defects in their blood stem cells. One of the novel therapies …
Back to top button
Close
Close